WHO Collaborating Centre for Gonorrhoea and other STIs, Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University Hospital and Örebro University, S. Grevrosengatan 2, SE-701 85 Örebro, Sweden.
Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, Oregon 97330, USA.
Nat Rev Urol. 2017 Nov;14(11):643-644. doi: 10.1038/nrurol.2017.139. Epub 2017 Aug 31.
Antimicrobial resistance in compromises gonorrhoea treatment globally and vaccines might be the only sustainable solution for gonorrhoea control. A new study for the first time provides a proof of principle for protection with ~31% effectiveness against gonorrhoea, owing to cross-protection by the outer membrane vesicle serogroup B vaccine (MeNZB).
抗菌药物耐药性使全球淋病治疗受到影响，而疫苗可能是控制淋病的唯一可持续解决方案。一项新的研究首次提供了一个原理性的证据，证明外膜囊泡血清群 B 疫苗 (MeNZB) 具有约 31%的交叉保护效力，可预防淋病。
